Compare Tempus AI (TEM) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs UnitedHealth Group Inc — how do they compare? Tempus AI trades at $70.25 (market cap $12.58B), while UnitedHealth Group Inc trades at $372.76 (market cap $332.96B). The key difference: UnitedHealth Group Inc is far larger — about 26.5× Tempus AI's market cap, and UnitedHealth Group Inc pays a 2.5% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tempus AI for 22 Days and UnitedHealth Group Inc for 97 Days on average.
| TEM | UNH | |
|---|---|---|
Market Cap | $12.58B | $332.96B |
Volume | 7,444,569 | 7,273,749 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.28 | $436.35 |
52-Week Low | $41.55 | $259.02 |
Typical Hold Time | 22 Days | 97 Days |
Enterprise Value | $13.21B | $374.82B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
UnitedHealth Group (UNH) trades at $375.98, showing minor daily weakness but maintaining a bullish technical signal. The company reported strong Q2 2026 earnings, beating estimates, and reaffirmed its full-year outlook. Revenue growth remains robust, though net margins have compressed from prior years. Analyst sentiment is overwhelmingly positive, with a consensus price target of $473.89 implying significant upside.
The outlook for UNH is favorable, driven by earnings momentum and strategic initiatives like AI investment. Key risks include regulatory pressures and medical cost trends. The stock presents a compelling opportunity for investors seeking exposure to a leading healthcare company with solid fundamentals and Wall Street support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
